In this issue:
Discontinuing adalimumab in JIA-associated uveitis
Uveitis rates with bimekizumab for axial spondyloarthritis
Olokizumab + methotrexate for RA
bDMARDs in patients with chronic kidney disease
IV golimumab for polyarticular-course JIA
Rituximab treatment in idiopathic inflammatory myositis
Cancer risks in patients with ankylosing spondylitis
Serum adalimumab and etanercept levels associated with PsA response
Methotrexate, tofacitinib and bDMARD safety and effectiveness in RA
Switching to bDMARDs vs cycling among JAK inhibitors in RA
Please login below to download this issue (PDF)